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ABSTRACT
Allergen-specific Th2 cells from atopic individuals generally 
belong to the T helper 2 (Th2) subset producing, among 
other cytokines, high levels of IL-4, IL-5 and IL-13, but low
levels of IL-2 and IFN-γ following activation. Both IL-4 and
IL-13 induce IgE synthesis, which is inhibited by IFN-γ. IL-4,
but not IL-13, also directs differentiation of naive CD4+ 
T cells into Th2 cells. Furthermore, IL-5 induces the differenti-
ation of eosinophils and eosinophilia, whereas IL-3, IL-4 and 
IL-10 produced by Th2 cells, synergize with c-kit ligand in 
promoting mast cell growth. These observations indicate that 
allergy is a Th2 cell disease, and that targeting of allergen-
specific Th2 cells may provide an efficient way to intervene in 
allergic inflammation.
 Three different approaches aimed at inhibiting the func-
tion or differentiation of allergen-specific Th2 cells are dis-
cussed. It is shown that an IL-4R and IL-13R antagonist 
inhibits IL-4-driven Th2 cell differentiation and human IgE 
production both in vitro and in SCID-hu mice. In addition, it 
is discussed that allergen-specific Th2 cells can be rendered 
anergic following stimulation with allergen-derived peptides, 
representing T cell activation inducing epitopes. These aner-
gic Th2 cells fail to produce IL-4, IL-5 and IL-13, to prolifer-
ate, and to provide help to B cells for IgE synthesis after 
rechallenge with allergen-and antigen-presenting cells.
 Finally, it is shown that IL-4-driven allergen-specific Th2 
cell differentiation can be redirected into a Th0 and Th1 cell 
differentiation pathway by stimulating these IL-4-driven aller-
gen-specific Th cell populations in the presence of IL-12, or 
by co-stimulating these cells via a novel T cell receptor, des-
ignated signalling lymphocyte activation molecule (SLAM). 
The clinical implications of these approaches are discussed.
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INTRODUCTION
Atopic patients produce enhanced levels of allergen-specific IgE 
antibodies in response to allergens, a capacity which is geneti-
cally determined. These allergen-specific IgE antibodies bind to 
high affinity IgE receptors expressed on mast cells and 
basophils, which are present in many tissues, particularly in the
mucosae. Entry of allergens through the airways, by skin contact 
or by ingestion results in cross-linking of receptor bound IgE and 
triggers the release of soluble mediators, such as histamines, 
prostaglandins and leukotrienes, which induce immediate aller-
gic responses, within minutes. In addition, chemotactic factors, 
chemokines, cytokines and factors which alter vascular per-
meability are produced. This results in the late phase response, 
which is characterized by an influx and accumulation of
eosinophils, neutrophils, basophils and lymphocytes at the site 
of the allergic reaction. These inflammatory cells and their prod-
ucts account for the chronic inflammation and tissue damage 
observed in the airway, skin and intestinal tract, which are con-
stantly exposed to allergens. Recently, considerable progress 
has been made in understanding the mechanisms underlying 
the pathogenesis of atopic disease. It has become clear that
T-cell-derived cytokines, interleukin 4 (IL-4) and IL-13, induce 
IgE synthesis by human B cells. In addition to these cytokines, 
contact-mediated signals delivered by interactions between the
CD40 ligand (CD40L), which is rapidly induced on T cells fol-
lowing activation, and CD40, which is constitutively expressed 
on B cells, are required for productive T-B cell interactions, 
resulting in immunoglobulin isotype switching and production.
Other cytokines, e. g. IFN-γ and IFN-α, inhibit IL-4 or IL-13-
induced IgE synthesis.1-4 
 Analysisof human T cell clones and T cells of atopic patients 
indicated that allergen-specific T cell responses are dominated 
by the T helper (Th)2 subset, which produce relatively high levels 
of IL-4, IL-13 and IL-5 and low, or non-detectable levels of
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IFN-γ. 5-7 Therefore, ollergen-specific Th2 cells are obvious tar-
gets for immune intervention in atopic disease. It will be dis-
cussed that inactivation, or prevention of differentiation of 
allergen-specific Th2 cells may improve the clinical status of 
allergic patients.
ALLERGEN-SPECIFIC TH2 CELLS
Although T cells from both atopic and non-atopic subjects pro-
liferate following stimulation with allergens, only T cells from 
atopics generally display a Th2 cytokine production profile.5 
These Th2 cells produce, among other cytokines, relatively high 
levels of IL-4, IL-5, IL-10 and IL-13 and generally low, and
sometimes undetectable levels of IFN-γ following activation.5-10
Th2 cells are found at sites of ongoing allergic reactions and in 
skin, or bronchial biopsies as a result of late phase reactions 
after allergen challenges in atopic or asthmatic patients.'o-15 
They are not found in non-atopic individuals. In addition, 
peripheral blood mononuclear cells (PBMC) of atopic patients
produce higher levels of IL-4 and lower levels of IFN-γ following
activation, than PBMC of healthy donors.16 In addition, PBMC 
of some atopic patients spontaneously produced IL-4, a phe-
nomenon which was never observed with PBMC of healthy 
donors.16 These observations further support the notion that 
enhanced IgE production in atopic patients is associated with 
enhanced levels of IL-4 production.
 Activation of allergen-specific Th2 cells by the relevant aller-
gens results in the expansion of these cells and production of 
cytokines, which play a pivotal regulatory role in the pathogen-
esis of human allergic diseases. IL-4 and IL-13 induce IgE 
switching and IgE synthesis by B cells, whereas IL-3, IL-4 and 
IL-10, in combination with c-kit ligand, induce mast cell prolif-
eration, IL-5 promotes the differentiation and survival of 
eosinophils and induces eosinophilia.17,18 Thus, Th2 cytokines 
account, not only for induction of IgE synthesis, but also for the 
expansion and differentiation of mast cells, basophils and 
eosinophils, all of which represent the hallmark of the allergic 
inflammation process.
INDUCTION OF NON-RESPONSIVENESS IN 
ALLERGEN-SPECIFIC TH2 CELLS
From these observations, it is clear that one approach to inter-
vene in allergic diseases is to inactivate allergen-specific Th2 
cells by rendering them non-responsive. Induction of allergen-
specific non-responsiveness in vitro was initially described for 
human Th clones, which were specific for the influenza virus.19 
Stimulation of these cells with the relevant virus-derived haemag-
glutinin peptide in the absence of professional antigen-
presenting cells (APC), resulted in failure of these cells to prolifer-
ate in response to restimulation with whole haemagglutinin pre-
sented by APC.19 More recently, a similar approach has been 
shown to be effective in inducing specific non-responsiveness in
allergen- pecific Th2 cells in vitro.20 Incubation of Der p1-specific 
Th2 clones with the relevant Der pl-derived peptides-in the 
absence of APC rendered the cells unresponsive to subsequent 
stimulation with intact Der pl and APC. These anergic cells fail to
proliferate and produce IL-2, IL-4, IL-5 and IL-13. In addition, no 
cytosolic calcium fluxes could be generated in these cells after 
stimulation with Der pl and ARC. However, the anergic Th2 cells
showed normal calcium fluxes and proliferated normally in 
response to stimulation with calcium ionophore and phorbol 
ester. In addition, IL-2 a chain expression was up-regulated on 
the anergic cells, and they proliferated normally in response to
exogenous IL-2. These results indicate that the anergic Th2 cells 
responded normally to signals, which circumvent triggering of 
the T cell receptor (TCR)/CD3 complex and suggest that peptide
mediated non-responsiveness is likely due to impaired signalling 
via the TCR. Furthermore, in contrast to their activated counter-
parts, the anergic CD4+ Th2 cells failed to provide help to B cells
for IgE synthesis, even in the presence of exogenous IL-4 or 
IL-13. Since the anergized Th2 cells expressed levels of CD40L, 
that were comparable with those on activated control Th2 cells, 
data indicate that CD40L-CD40 interactions in the presence of
IL-4, or IL-13 are insufficient to induce IgE synthesis and suggest 
that additional, yet to be defined, signals might be required for 
the initiation of T-B cell interactions resulting in IgE production.
 Addition of IL-2 restored the helper activity of the anergic Th2 
clones to a certain extent, which resulted in low levels of IgE syn-
thesis, whereas combinations of IL-2 and IL-4, or IL-2 and IL-13 
had synergistic effects, inducing levels of IgE synthesis that were
higher than those obtained with Der pl activated control Th2 
cells.20 Collectively, the data indicate that incubation of allergen-
, specific Th2 cells with the relevant allergen-derived peptide not
only prevented allergen-specific activation and cytokine produc-
tion by these cells, but also abolished their helper function for IgE 
synthesis.
 Optimal induction of T cell effector function generally requires 
ligation of TCR by antigenic peptide-MHC complexes and co-
stimulatory signals provided by interaction between CD28 on 
T cells and ligands CD80 and CD86 on APC.21-24 Human T cell
clones express class II MHC molecules constitutively, and there-
fore can present antigenic peptides to each other, but despite 
human T cell clones expressing functional CD80 and CD86 mol-
ecules, which can trigger CD28-mediated co-stimulatory signals, 
activation of allergen-specific Th2-like T cell clones by allergen-
derived peptides in the absence of APC, resulted in Th2 cell
anergy.20,24,25 In addition, non-responsiveness of the Der pl-
specific Th2 clones could not be reversed by stimulating the cells 
with Der pl in the presence of autologous CD80/CD86-express-
ing EBV-transformed B cell lines, L cells transfected with CD80, or 
anti-CD28 mAb.20 These results support the notion that mere 
expression of CD80 and CD86 on human T cell clones during
incubation with allergen-derived peptides is not sufficient for T cell 
proliferation and that interactions between CD28 and CD80, or 
CD86 on T cells, may not be comparable with those between 
T c lls a d professional APC.
IMMUNE INTERVENTION IN ALLERGIC DISEASE 119
IN VIVO MODELS OF T CELL ANERGY
Animal studies have shown that immunization with peptides rep-
resenting dominant T cell epitopes can induce antigen-specific
non-responsiveness and successful treatment of autoimmune dis-
eases.26-30 Thus, peptides representing T cell epitopes also have 
tolerogenic activity in vivo, as a result of induction of antigen-
specific T cell non-responsivensss. At present, there is little infor-
mation on the ability to tolerize allergen-specific Th2 cell 
responses in vivo. However, successful peptide vaccination
observed in experimental autoimmune diseases, and the capacity 
of allergen-derived peptides to induce allergen-specific Th2 cell 
non-responsiveness in vitro, suggest that allergen-derived pep-
tides may also have potential utility for inducing specific Th2 cell 
non-responsiveness to allergens in vivo, which would allow spe-
cific desensitization of allergic inflammatory responses in atopic
patients. Despite the controversy surrounding the ability to tolerize 
Th2 cells in vivo,28,29 subcutaneous immunization with a dominant 
peptide of the major cat allergen Fel dl resulted in decreased T 
cell responses, as measured by reduced IL-2 production to subse-
quent challenge with this peptide in Fel dl primed mice. 
Furthermore, pretreatment of mice with two Fel dl-derived 
immunodominant peptides induced T cell tolerance to a subse-
quent challenge with the entire recombinant Fel dl chain 1, sug-
gesting that peptides containing some of the T cell epitopes in a 
large polypeptide can tolerize T cells for subsequent challenge
with that larger polypeptide protein.29 
 Recently, the effects of immunotherapy on cytokine production 
patterns of T cells from atopic patients were analysed. In vitro IL-
4 production by allergen-specific T cells from patients who had 
been successfully treated, was reduced to levels that were com-
parable with those observed from non-allergic individuals,
whereas IL-2 and IFN-γ production by these cells was not
affected.29,31 Polyclonal serum IgE levels were not reduced in suc-
cessfully treated patients, which, however, does not rule out the
possibility that allergen-specific serum IgE levels could have been 
down-regulated in these patients. Although it remains to be 
determined whether these observations reflect reduced respon-
siveness of allergen-specific IL-4-producing Th2 cells to allergen 
challenge, these data indicate that the cytokine production pro-
files of allergen-specific T cells as reflected in their reduced IL-
4:IFN-γ ratios, can be modulated in vivo.
PEPTIDE VACCINATION OF ALLERGIC PATIENTS
The studies described above suggest that it may be possible to use 
peptide-induced T cell tolerance to treat severe human allergies. 
Although this possibility remains to be established, it is tempting to
speculate that peptide-induced, allergen-specific T cell non-
responsiveness may also account for successful immunotherapy.
Present information indicates that ideally, high concentrations of 
allergen-derived peptides, containing T cell activation-inducing 
epitopes, should be administered in order to by-pass professional
APC and to render the allergen-specific T cell directly anergic. 
Theoretically, this would be feasible, because peptides containing 
minimal T cell epitopes do not induce histamine release from sen-
sitized basophils, since they are unable to bind IgE antibodies and 
therefore, cannot cause anaphylactic reactions (H. Yssel unpubl. 
data). However, it has to be taken into account that high levels of
IL-4 and IL-5 were produced during induction of the T cell anergy 
process in vitro, e. g. during incubation of the Der pl-specific cell 
clones with the relevant Der pl-derived peptides (S. Fasler and H.
Yssel upubl. data). Since it is not unlikely that this also might 
happen during initiation of peptide vaccination in vivo, it is a 
problem that should be dealt with.
 Another major problem is that most allergens contain multiple 
T cell activation-inducing epitopes. In addition, peptides represent-
ing these epitopes are restricted by different MHC class II antigens,
which emphasizes the heterogeneity of T cell responses to aller-
gens.7 Although the Fel dl studies mentioned above,29 and other 
mouse studies have indicated that total T cell responses to complex
native proteins can be limited to a few immunodominant epi-
topes.32-34 T cells can escape the induction of tolerance in the pres-
ence of other, non-immunodominant T cell epitopes, which
b come available after in viva processing of native antigen.35 
Coll ctively, this information implies that optimal immunotherapy 
for each patient requires mapping of all individual T cell epitopes,
as well as precise HLA typing. This approach is presently impractical 
for large scale treatment of allergies, but the principle of this type of 
immunotherapy could be explored in selected individual patients.
 One possible practical way to circumvent this problem of indi-
vidual 'tailor-made' immunotherapy is to administer mixtures of 
overlapping allergen-deprived peptides representing all T cell
activation-inducing epitopes on the corresponding native aller-
gen. The advantage of this approach is that it does not require 
mapping of all T cell activation-inducing epitopes. In addition,
precise MHC class 11 typing of patients is not required. As short 
allergen-derived peptides do not react with antibodies, and there-
fore are unable to induce anaphylactic reactions, they seem to be
ideal for induction of human Th2-cell tolerance in vivo. One 
clinical trial, which is based on vaccinating cat allergic patients 
with immunodominant peptides derived from the major cat aller-
gen Fel dl, is presently in progress. The outcome of this clinical 
trial will provide more information on the efficacy and safety of 
this type of therapy. It should be noted, however, that this trial is
being carried out with only two peptides containing immunodom-
inant T cell epitopes, whereas the Fel dl molecule contained many
more minor T cell activation-inducing epitopes, which may pre-
vent efficient tolerance induction in a proportion of the patients.
It seems, therefore, fair to conclude that in spite of these promis-
ing results much more information needs to be obtained before
p ptide-induced non-responsivensss in human allergen-specific
Th2 cells can be used for immunotherapy in allergic patients.
INHIBITING AND REDIRECTING ALLERGEN-SPECIFIC
TH2 CELL DIFFERENTIATION
Another way to inhibit allergen-specific Th2 responses would
be to prevent or inhibit the development of these cells in viva.
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The mechanisms by which allergen-specific Th2 cells develop in 
allergic patients are still ill-defined. However, mouse studies 
have shown that initial allergen-specific activation of naive
T cells in the presence of IL-4 results in the generation of IL-4 and 
IL-5 producing Th2 cells both in vitro and in vivo, whereas differ-
entiation of IFN-γ. producing Th1 is inhibited.36-38 In contrast,
IL-12, which is produced by monocytes/macrophages, dendritic 
cells and B cells, is the dominant factor in inducing the differenti-
ation of IFN-γ producing antigen-specific Th1 cells from naive
CD4+ T cells.33-40 Interestingly, IL-12 also transiently induces or
enhances IFN-γ production by allergen-specific human Th2
clones in vitro, indicating that the cytokine production profile of 
these T cell clones is not stable and still can be modulated.41,42 
Furthermore, in vitro activation of PBMC from allergic patients by
the relevant allergens in the presence of IFN-γ, IFN-α, or IL-12
resulted in a preferential outgrowth of cells with a Thl -like phe-
notype, instead of the normal Th2-like cytokine profile.43,44 These 
observations suggest that the cytokine profiles of human T cell
populations, which have been exposed to allergens in vivo for 
prolonged periods of time, still can be redirected in vitro. On the 
other hand, it may be possible that the apparent reversal of the
cytokine profile of the allergen-specific Th2 subset, in the latter 
study, is due to differentiation of uncommitted T cells among 
these cell populations into Th1-like cells. 
 Recently, we have shown that IL-4 induces differentiation of
naive human CD4+, CD45RA+ T cells obtained from cord 
blood. Repetitive activation of these cells, with cross-linked anti-
CD3 mAB, resulted in the generation of IL-4-, II-5- and IL-13-
producing cells as judged by the intracellular presence of these 
cytokines at an individual T cell level.45 In contrast, the frequen-
cies of Th1 cells producing only IFN-γ, or Th0 cells producing
IFN-γ and IL-4 simultaneously, were low, but not completely
absent, indicating that IL-4 did not totally prevent the differenti-
ation of Th1, and Th0 cells. The T cell differentiation inducing 
effects of IL-4 were direct. In contrast, IL-13, which like IL-4
induces IgE production by B cells, fails to induce Th2 cell differ-
entiation, which is consistent with the observation that IL-13 
does not act on T cells. More importantly, this observation illus-
trates that the absence of IL-13 receptors on T cells may have 
major biological consequences, in that IL-13, despite that it 
induced IgE synthesis, cannot direct Th2 cell development,
which reflects the hallmark of allergic disease. Therefore, one 
might speculate that IL-4 is the more dominant cytokine in driv-
ing and maintaining allergic responses. First, however, it needs
to be confirmed that IL-13 indeed fails to induce Th2 develop-
ment in vivo in mouse models, in which IL-4 is effective. This is of 
importance, since IL-13 may still indirectly favor the generation 
of Th2 cells because of its capacity to downregulate the produc-
tion of IFN-α and IL-12, cytokines which both direct Th1 devel-
opment.43,44,46 
 Repetitive stimulation of the CD45RA+ cord blood T cells with 
cross-linked anti-CD3 mAb in the presence of IL-12 induced
high frequencies of IFN-γ producing Th1 cells, very loW fre-
quencies of IFN-γ and IL-4 producing Th0 cells and virtually no
IL-4 producing Th2 cells. Interestingly, addition of IL-12 
together with IL-4 resulted in significant changes in ~he cytokine 
production profiles. A reduction in IL-4-producing Th2 cells
accompanied by strong increases in IL-4-and IFN-γ-producing
Th0 and particularly IFN-γ producing Th1 cells was observed
compared with CD45RA+ cells activated in the presence of IL-4 
alone.45 These results indicate that IL-12 can reverse IL-4-driven 
Th2 cell differentiation at the population level in vitro. Whether
the generation of IFN-γ-producing cells reflects an actual rever-
sal in cytokine production profiles of individual Th2 cells, or
induction of IFN-γ producing cells from a pool of non-commit-
ted T cells, however, remains to be established. 
 Fully polarized murine Th1 or Th2 cells seem to be more resis-
tantto a reversal in their cytokine production patterns. Particularly, 
IL-4-producing mouse Th2 cells appear to be resistant to the
effects of IL-12 and anti-IL-4 mAb, which may reflect a down-
regulation of receptors for Th1 induction on these cells.47,48 On 
the other hand, recently it has been shown that administration of
IL-12 to mice reverses detrimental Th2 responses to chronic 
Leishmania major infections to healing Th1 responses, when 
given with a drug, which reduces the parasite load.49 These results
indicate, that under certain conditions, also polarized mouse Th2 
responses still can be modulated in vivo. Whether administration
of IL-12, or up-regulation of endogenous IL-12 will be effective in 
redirecting established allergen-specific Th2 responses in allergic 
patients, remains to be determined.
STIMULATION OF T CELLS VIA SIGNALLING 
LYMPHOCYTE ACTIVATION MOLECULE CHANGES THE 
CYTOKINE PRODUCTION PROFILE OF TH2 CELLS
Recently, we described a novel 70 kDa T cell surface receptor, 
which is constitutively expressed on CD4+, CD45RO+ memory T
cells, immature and CD4+, CD8+ thymocytes and a subset of 
peripheral blood B cells.50 In addition, signalling lymphocyte acti-
vation molecule (SLAM) is rapidly induced on all T and B cells fol-
lowing activation. Ligation of SLAM with an agonistic anti-SLAM
mAb resulted in enhanced antigen-specific T cell responses, indi-
cating that SLAM is involved in co-stimulation of human peripheral
blood T cells. In addition, anti-SLAM mAb can directly induce pro-
liferation and expansion of T cells, once they are activated by anti-
gen. Co-activation of T cell clones with the agonistic anti-SLAM
mAb induced or enhanced IFN-γ production, even in allergen-
specific Th2-like T cell clones. The levels of IFN-γ production by
the Th2 clones following activation by allergen and APC in the 
presence of anti-SLAM mAb were comparable with those induced 
by antigen and ARC in Th1 or Th0 clones.
In contrast to its IFN-γ-inducing effects on Th2 clones, the
anti-SLAM mAb failed to induce IL-4 and IL-5 production by Thl 
clones. Furthermore, use of SLAM had only minor, or no enhanc-
ing effects on IL-4 and IL-5 production by antigen-activated Th2 
or Th0 clones. These results indicate that interaction between 
SLAM and its putative ligand further enhance antigen-specific
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Th2-cell expansion, while inducing IFN-γ production by these
cells, thereby reversing the cytokine production profile of these 
cells in a Th0 phenotype. In contrast, the cytokine production 
pattern defining Thl clones is not significantly altered by con-
comitant stimulation via SLAM. Furthermore, these results are 
comparable with the notion that allergen-specific human Th2-
like clones, producing relatively high levels of IL-4 and lL-5, still
have the capacity to produce IFN-γ, further supporting the
notion that the IFN-γ gene is not silent in these cells. Preliminary
in vitro data have indicated that anti-SLAM mAb indeed act like 
IL-12, in redirecting IL-4-driven allergen-specific Th2 cell differ-
entiation. Relatively high frequencies of IFN-γ-producing T cells
were generated in cultures, in which allergen-specific Th2 cells 
were repetitively stimulated with allergen in the presence of IL-4
and the agonistic anti-SLAM mAb (Carballido and de Vries 
unpubl. data). These data provide an attractive basis for the 
hypothesis that engagement of SLAM by its putative ligand may
also favor the development of IFN-γ-producing cells by down-
regulating the generation of allergen-specific Th2 cells in vivo.
IFN-γ produced under these conditions may also coun+erad the
IgE-inducing effects of IL-4 and IL-13, thereby ameliorating IgE-
mediated allergic diseases.
CONCLUDING REMARKS
Allergen-specific CD4+ Th2 cells producing, among other 
cytokines, high levels of IL-4, IL-5, IL-10 and IL-13, play a key 
role in the induction and maintenance of allergic diseases. 
Despite initial reports that allergen-specific Th2 cells failed to
produce detectable levels of IFN-γ,5,6 it is becoming clear now
that the T cells generally also produce low levels of IFN-γ, fol-
lowing allergen-specific stimulation, which can be considerably 
upregulated by stimulating the cells with calcium ionophore and 
phorbol myristate acetate (PMA).7-10 However, based on their
high IL-4:IFN-γ produdion ratios, these cells are considered
'Th2 -like'. Here, it is discussed that targeting these T cells may 
provide efficient ways to intervene in allergy. Allergen-specific 
Th2-like cells can be rendered unresponsive in vitro following 
incubation with the relevant allergen-derived peptides. Based
on these observations, and data demonstrating peptide vacci-
nation in mouse models leads to antigen-specific T cell non-
responsiveness in vivo, it is tempting to speculate that induction 
of Th2-cell tolerance represents the underlying mechanisms of 
successful immunotherapy.
 IL-4 is an essential factor for driving Th2 cell differentiation, 
but the cellular source of IL-4, which needs to be present during 
allergen priming, has not been determined yet. Mast cells and 
basophils, which produce IL-4 have been implicated,51-53 but 
recent studies in IL-4-deficient mice reconstituted with only
CD4+ T cells from congenic wild-type animals have been shown 
that these mice are able to produce antigen-specific IgE, in the 
absence of mast cell and basophils.54 A recently described sub-
set of mouse CD4+ NK1. 1+T cells, which produce IL-4 fol-
lowing activation in vivo, is considered as another potential 
source of IL-4.55 Although its human counterpart still needs to be 
identified, studies on the role of these cells in setting the stage
for Th2 responses are presently in progress in various laborato-
ries. In allergy, specialized APC, such as Langerhans cells and
dendritic cells present in the skin and the respiratory mucosa, 
which are the major ports of entry of allergens are probably 
responsible for allergen-specific T cell priming. Therefore, it
cannot be ruled out that these specialized APC or specific fac-
ors produced by these cells may direct the Th2 differentiation 
process in atopic allergy.
 The cyt kine production profiles of allergen-specific Th2 cells 
from allergic patients can be modulated in vitro and in vivo. 
Activation of these cells in the presence of IL-12, or agonistic
anti-SLAM mAb induce or enhance IFN-γ production　in vitro. In
addition, successful immunotherapy reduces the level of IL-4 
pro uction by allergen-specific T cells.31 However, whether IL-
12, or anti-SLAM mAb treatment or signals, which mimic IL-12
receptor or SLAM activation pathways, will be effective in redi-
recting allergen-specific Th2 responses in allergic individuals 
into Th0/Th1 responses, remains to be determined. Since 
induction of antigen-specific Th cell differentiation requires both
TCR and cytokine-mediated signals, the prediction is that pep-
tide vaccination combined with cytokine (IL-12) therapy would 
be most efficient in redirecting existing allergen-specific Th2 
responses.
 Non-atopic individuals fail to develop allergic responses, 
indicating that genetic factors play an important role in Th2 dif-
ferentiation. Recent evidence has indicated that enhanced IgE 
production in atopy is linked to chromosome 5q31.1, an area 
where the genes for IL-4 and IL-13 are mapped.56 These obser-
vations suggest that differential regulation of IL-4 and IL-13 
gene expression in atopic and healthy individuals could con-
tribute to Th2 development in atopic disease. On the other
hand, down-regulation of other cytokine genes, such as those 
encoding Thl differentiation, or suppressing IgE synthesis can-
not be excluded. Generation of more defined information about
transcriptional regulation of cytokine genes associated with Thl 
and Th2 development will result in new insights in the potential 
geneti  basis of Th2 development.
 In the next few years, the contribution of Th2 cells to the aller-
gic inflammation process and IgE synthesis will be further 
defined, and will result in novel opportunities for more efficient 
intervention in the allergic disease process.
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